About | Free Trial

Last Update

2015-02-10T00:00:00.000Z

This profile was last updated on // .

Is this you? Claim your profile.

Wrong Mark Gelder?

Dr. Mark Gelder S. MD

Senior Vice President and Chief Medical Officer

Heron Therapeutics Inc

HQ Phone: (650) 366-2626

Heron Therapeutics Inc

123 Saginaw Drive 123 Saginaw Drive

Redwood City, California 94063

United States

Company Description

Heron Therapeutics, Inc. (NASDAQ: HRTX) is a specialty pharmaceutical company developing products using its proprietary Biochronomer™ polymer-based drug delivery platform. This drug delivery platform is designed to improve the therapeutic profile of injec ... more

Find other employees at this company (80)

Background Information

Employment History

Senior Vice President and Chief Marketing Officer
A.P. Pharma Inc

Vice President, Global Head Medical Affairs and PV, Medical Diagnostics and NPD
GE Healthcare Ltd

Education

B.S. degree
biochemistry
Colgate University

M.D.

M.D. degree

University of Virginia's School of Medicine

Web References (81 Total References)


Heron Therapeutics • A Biotechnology Company

www.herontx.com [cached]

Mark Gelder, M.D. Senior VP, Chief Medical Officer

...
Mark Gelder, M.D. Senior VP, Chief Medical Officer
Mark S. Gelder, M.D. joined Heron Therapeutics as Senior Vice President and Chief Medical Officer in December 2012. From October 2007 to December 2011, Dr. Gelder was the Vice President and Global Head of Medical Affairs and Pharmacovigilance at GE Healthcare Medical Diagnostics. During his tenure at GE Healthcare, he led the global medical affairs strategy, including preparation and execution of medical launch plans. He was also responsible for global Phase IV and other post-approval commitment studies. Prior to GE Healthcare, Dr. Gelder was the Vice President of Global Medical Affairs of Oncology for Bayer HealthCare Pharmaceuticals, and was responsible for the global medical strategy supporting the launch of Nexavar® (sorafanib), Stivarga® (regorafenib), and Alpharadin® (now called Xofigo )(radium 223 dichloride) global programs. Dr. Gelder was also the Global Therapeutic Area Director of Oncology at Wyeth from December 2005 to October 2007, with a focus on the commercial launch of Torisel® (temsirolimus). Earlier in his career, Dr. Gelder held roles of increasing responsibility at Pfizer, Inc., working on Sutent® (sunitinib malate), and was also a practicing gynecologic oncologist in both the academic and private sectors. Dr. Gelder received his B.S. degree in biochemistry from Colgate University, and his M.D. degree from the University of Virginia's School of Medicine.


Mark S. Gelder ...

phx.corporate-ir.net [cached]

Mark S. Gelder


Heron Therapeutics . A Biotechnology Company • Investor Relations • News Release

phx.corporate-ir.net [cached]

A.P. Pharma Names Mark S. Gelder, M.D. as Senior Vice President and Chief Medical Officer

...
A.P. Pharma Names Mark S. Gelder, M.D. as Senior Vice President and Chief Medical Officer
...
Mark S. Gelder , M.D. as senior vice president and chief medical officer. The addition of Dr. Gelder to A.P. Pharma’s executive team represents the Company’s continued efforts related to pre-commercialization activities for APF530, the Company’s lead product candidate for the prevention of chemotherapy-induced nausea and vomiting, if approved.
...
Dr. Gelder, most recently, was the vice president and global head of medical affairs and pharmacovigilance at GE Healthcare Medical Diagnostics. During his tenure, he led the global medical affairs strategy, including preparation and execution of medical launch plans. He was also responsible for global Phase IV and other post-approval commitment studies. Prior to GE Healthcare , Dr. Gelder was the vice president, global medical affairs oncology for Bayer Healthcare Pharmaceuticals , and was responsible for the global medical strategy supporting the launch of Nexavar®, Stivarga®, and Alpharadin® global launch programs. Dr. Gelder was also the global therapeutic area director of oncology at Wyeth , with a focus on the commercial launch of Torisel®. Earlier in his career, Dr. Gelder held roles of increasing responsibility at Pfizer, working on Sutent®, and was also a practicing gynecologic oncologist in both the academic and private sectors. Dr. Gelder received a bachelor’s of science degree from


Heron Therapeutics . A Specialty Pharmaceutical Company • Investor Relations • News Release

phx.corporate-ir.net [cached]

, the Company announced the appointment of Mark S. Gelder, M.D. as Senior Vice President and Chief Medical Officer.


Heron Therapeutics . A Biotechnology Company • Investor Relations • 2012 News Releases

phx.corporate-ir.net [cached]

A.P. Pharma Names Mark S. Gelder, M.D. as Senior Vice President and Chief Medical Officer

...
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Dec. 13, 2012-- A.P. Pharma, Inc. (OTCBB: APPA.OB), a specialty pharmaceutical company, today announced the appointment of Mark S. Gelder, M.D. as senior vice president and chief medical officer. The addition of Dr. Gelder to A.P. Pharma’s executive team represents the Company’s continued efforts related to pre-commercialization activities for APF530, the Company’s lead product candidate for the prevention of chemotherapy-induced nausea and vomiting, if app...Â

Similar Profiles

Other People with this Name

Other people with the name Gelder

Brenda Van Gelder
Banda Group International LLC

Daniel Van Gelder
New West End Company

Don van Gelder
Cassiopae Inc

Brenda Van Gelder
Fiserv Inc

Janet Van Gelder
Tahoe Forest Hospital

Browse ZoomInfo's Business Contact Directory by City

Browse ZoomInfo's
Business People Directory

Browse ZoomInfo's
Advanced Company Directory